Title: THSD7A as a novel prognostic factor for colorectal carcinoma
Version: 1 Date: 07 Feb 2025
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
Dear Authors, please address the following points below
-While the introduction explains the rationale behind the study, it could be clearer about the
specific research questions. For example, the introduction could more explicitly state whether the
focus is solely on THSD7A as a biomarker for overall survival, or whether it will also consider
its role in disease progression or response to treatment.
-It would be beneficial to briefly mention how THSD7A expression could impact clinical
decision-making or guide therapeutic strategies in CRC, which would help emphasize the
potential translational value of the study's findings.
-While the immunohistochemistry procedure is well-described, the threshold for categorizing
tumors as positive or negative (#1% expression of cancer cells) could be clarified. For instance,
why is 1% used as the cutoff for "positive" expression, and how does this compare with other
studies using similar methodologies? Further justification for this threshold would add clarity.
-While the inclusion criteria are outlined, the description of patient demographics (age, sex, etc.)
is absent. Including this information would be helpful to assess the representativeness of the
cohort. For example, how might age, sex, or tumor location impact THSD7A expression and
survival outcomes?
-While the discussion highlights THSD7A's role in angiogenesis, it could benefit from further
explanation of its exact molecular mechanisms. For example, how exactly does THSD7A
contribute to angiogenesis at the molecular level, and what are the signaling pathways involved?
Adding more details on this could strengthen the argument for THSD7A as a therapeutic target.
-The discussion acknowledges the variability in results across studies regarding THSD7A
expression and its association with pathological features. However, it could benefit from a more
in-depth exploration of these inconsistencies. For instance, what factors (such as sample size,
tissue types, or patient characteristics) might explain the differences in THSD7A expression or
its prognostic significance between studies? This would provide a more nuanced understanding
of the literature and help contextualize the study's results more comprehensively.
-The discussion mentions a lack of association between THSD7A expression and adverse
pathological features in the present study, except for lymphovascular invasion (LVI). It would
be useful to explore why LVI is the only feature correlated with THSD7A expression and what
this may imply about the role of THSD7A in CRC progression. Does this suggest a specific role
for THSD7A in vascular invasion and metastasis?
Title: THSD7A as a novel prognostic factor for colorectal carcinoma
Version: 1 Date: 07 Feb 2025
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
Dear Authors, please address the following points below
-While the introduction explains the rationale behind the study, it could be clearer about the
specific research questions. For example, the introduction could more explicitly state whether the
focus is solely on THSD7A as a biomarker for overall survival, or whether it will also consider
its role in disease progression or response to treatment.
-It would be beneficial to briefly mention how THSD7A expression could impact clinical
decision-making or guide therapeutic strategies in CRC, which would help emphasize the
potential translational value of the study's findings.
-While the immunohistochemistry procedure is well-described, the threshold for categorizing
tumors as positive or negative (#1% expression of cancer cells) could be clarified. For instance,
why is 1% used as the cutoff for "positive" expression, and how does this compare with other
studies using similar methodologies? Further justification for this threshold would add clarity.
-While the inclusion criteria are outlined, the description of patient demographics (age, sex, etc.)
is absent. Including this information would be helpful to assess the representativeness of the
cohort. For example, how might age, sex, or tumor location impact THSD7A expression and
survival outcomes?
-While the discussion highlights THSD7A's role in angiogenesis, it could benefit from further
explanation of its exact molecular mechanisms. For example, how exactly does THSD7A
contribute to angiogenesis at the molecular level, and what are the signaling pathways involved?
Adding more details on this could strengthen the argument for THSD7A as a therapeutic target.
-The discussion acknowledges the variability in results across studies regarding THSD7A
expression and its association with pathological features. However, it could benefit from a more
in-depth exploration of these inconsistencies. For instance, what factors (such as sample size,
tissue types, or patient characteristics) might explain the differences in THSD7A expression or
its prognostic significance between studies? This would provide a more nuanced understanding
of the literature and help contextualize the study's results more comprehensively.
-The discussion mentions a lack of association between THSD7A expression and adverse
pathological features in the present study, except for lymphovascular invasion (LVI). It would
be useful to explore why LVI is the only feature correlated with THSD7A expression and what
this may imply about the role of THSD7A in CRC progression. Does this suggest a specific role
for THSD7A in vascular invasion and metastasis?
Please review this paper.
user
Title: THSD7A as a novel prognostic factor for colorectal carcinoma
Version: 1 Date: 07 Feb 2025
Reviewer:  Anwar Ashraf Abouelnasr
Reviewer's report:
Dear Authors, please address the following points below
-While the introduction explains the rationale behind the study, it could be clearer about the
specific research questions. For example, the introduction could more explicitly state whether the
focus is solely on THSD7A as a biomarker for overall survival, or whether it will also consider
its role in disease progression or response to treatment.
-It would be beneficial to briefly mention how THSD7A expression could impact clinical
decision-making or guide therapeutic strategies in CRC, which would help emphasize the
potential translational value of the study's findings.
-While the immunohistochemistry procedure is well-described, the threshold for categorizing
tumors as positive or negative (#1% expression of cancer cells) could be clarified. For instance,
why is 1% used as the cutoff for "positive" expression, and how does this compare with other
studies using similar methodologies? Further justification for this threshold would add clarity.
-While the inclusion criteria are outlined, the description of patient demographics (age, sex, etc.)
is absent. Including this information would be helpful to assess the representativeness of the
cohort. For example, how might age, sex, or tumor location impact THSD7A expression and
survival outcomes?
-While the discussion highlights THSD7A's role in angiogenesis, it could benefit from further
explanation of its exact molecular mechanisms. For example, how exactly does THSD7A
contribute to angiogenesis at the molecular level, and what are the signaling pathways involved?
Adding more details on this could strengthen the argument for THSD7A as a therapeutic target.
-The discussion acknowledges the variability in results across studies regarding THSD7A
expression and its association with pathological features. However, it could benefit from a more
in-depth exploration of these inconsistencies. For instance, what factors (such as sample size,
tissue types, or patient characteristics) might explain the differences in THSD7A expression or
its prognostic significance between studies? This would provide a more nuanced understanding
of the literature and help contextualize the study's results more comprehensively.
-The discussion mentions a lack of association between THSD7A expression and adverse
pathological features in the present study, except for lymphovascular invasion (LVI). It would
be useful to explore why LVI is the only feature correlated with THSD7A expression and what
this may imply about the role of THSD7A in CRC progression. Does this suggest a specific role
for THSD7A in vascular invasion and metastasis?
assistant